Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Debt is the top economic issue for U.S. voters. Boeing strike ends as workers accept latest contract offer. Viking stock ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Viking Therapeutics (VKTX) is up more than +5% after the company’s experimental pill, VK2735, showed weight loss in patients at higher doses with limited side effects. Air Transport Services Group ...

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

Lattice Semiconductor slipped 4% Tuesday after the company released its latest financial results, but the new CEO eyes ...

Two tragic incidents in Phuket resulted in the drowning deaths of a five year old Chinese boy and a 43 year old British tourist, police confirmed yesterday. Karon Police were notified by Chalong ...